IRIDINA DUE COLL 10ML 0.5MG/ML

IRIDINA DUE 0.5MG/ML COLLECTION

active ingredients

10 ml of eye drops contain nafazoline hydrochloride 5 mg Eccipients with known effects: For the complete list of excipients, see paragraph 6.1

Excellent

Sodium chloride, Sodium hydrogen phosphate dihydrate, Sodium hydroxide, Sodium Hyaluronate, Benzalconio Chloride, Hamamelis distillate water, Chamomile distillate water, Purified water

Therapeutic indications

Irritation, burning, redness of the eye, with excessive tearing, and sensitivity to light.

Contraindications

Hypersensitivity to the active ingredient or other substances strictly related to the chemical point of view (in particular xilometazolina, oximetazolina, tetrizolina) or to any of the excipients listed in the paragraph 6.1. The product should not be used in patients with glaucoma or other eye diseases. Contraindicated in children under twelve years. Contraindicated in case of treatment with MAO inhibitors (see paragraph 4.5).

Population

When you feel the burning sensation, squeeze one or two drops of eye drops into the inner corner of each eye, tilting backwards the head. The product should not be used after 28 days from the first opening. The medicinal product should not be used for more than 4 consecutive days, unless otherwise indicated by the doctor. Strictly stick to the recommended doses. A higher dose of the product, even if taken in a topical and short period of time, can give rise to serious systemic effects.

Conservation

This medicine does not require any special condition of conservation. The validity period after opening the bottle is 28 days.

Warnings

In case of persisting or aggravating symptoms after drinking period of treatment, consult your doctor, in any case, the product should not be used for more than 4 consecutive days. (see paragraph 4.2) If you have the appearance of undesirable effects (ocular pain, changes in vision or persisting redness) in a period of less than 4 days interrupt therapy and consult your doctor. The product is not suitable for the treatment of infections, pus, foreign bodies in the eye, mechanical, chemical and heat damage. Such conditions require the attention of the doctor. The product, while presenting a poor serum absorption, should be used with caution in patients suffering from hypertension, hyperthyroidism, heart disorders, hyperglycemia (Diabete) and bronchial asthma. Because the product contains Benzalconio Cloruro, soft contact lenses should not be worn during treatment. In case of use of contact lenses, these must be removed before the instillation of the colliery and can be reapplied after 15 minutes. Keep out of reach of children since accidental ingestion can cause depression S.N.C. (sighted separation of hypotonia, coma). In these cases it is always immediate medical assistance is required.

Interactions

MAO- inhibitors enhance the pharmacological effects of nafazoline. Contemporary use is not recommended. Allow you to spend at least two weeks between the start of nafazoline therapy and the end of that with MAO inhibitors.

Effects

The use of the product can sometimes cause pupilal dilation, systemic effects from absorption (hypertension, heart disorders, hyperglycemia), increased endoocular pressure, nausea, headache. Rarely, phenomena of hypersensitivity can occur. In this case it is necessary to stop the treatment and consult the doctor so that, where necessary, appropriate therapy can be established. Very rarely have been reported cases of cornea calcification associated with the use of phosphates in patients with significantly damaged cornea. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse

Overdosing

In case of overdose due to accidental administration for os, especially in children, depression can occur at the central nervous system level with bradypnea phenomena, feeling of cold to the skin, drowsiness, tachycardia, sweating, mental confusion and coma. If this happens: gastric lavender, sedation with diazepam and general support measures.

Pregnancy There is no data on the use of nafazoline in pregnant women. The colliery IRIDINA DUE should only be administered if the potential benefit justifies the potential risk for the fetus. Breasting No data are available on the possible excretion of the active ingredient through breast milk. Risk in infants/children cannot be excluded.

Source: Farmadati